Latest Insider Transactions at Kinnate Biopharma Inc. (KNTE)
This section provides a real-time view of insider transactions for Kinnate Biopharma Inc. (KNTE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kinnate Biopharma Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kinnate Biopharma Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 03
2024
|
Mark A Meltz COO GENERAL COUNSEL SECRETARY |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,578
-100.0%
|
-
|
|
Apr 03
2024
|
Keith T. Flaherty |
SELL
Sale (or disposition) back to the issuer
|
Direct |
66,377
-100.0%
|
-
|
|
Apr 03
2024
|
Neha Krishnamohan CHIEF FINANCIAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
64,087
-100.0%
|
-
|
|
Apr 03
2024
|
Nima Farzan CHIEF EXECUTIVE OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,186
-100.0%
|
-
|
|
Apr 03
2024
|
James B. Tananbaum |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
13,718,311
-100.0%
|
-
|
|
Apr 03
2024
|
Carl L Gordon Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
8,009,729
-100.0%
|
-
|
|
Apr 03
2024
|
Orbimed Advisors LLC Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
8,009,729
-100.0%
|
-
|
|
Apr 03
2024
|
Foresite Capital Management Iv, LLC > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
13,718,311
-100.0%
|
-
|
|
Mar 01
2024
|
Richard Thomas Williams CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
558
-0.82%
|
$1,116
$2.59 P/Share
|
|
Mar 01
2024
|
Mark A Meltz COO GENERAL COUNSEL SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
558
-1.98%
|
$1,116
$2.59 P/Share
|
|
Mar 01
2024
|
Neha Krishnamohan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,506
-2.3%
|
$3,012
$2.59 P/Share
|
|
Dec 01
2023
|
Mark A Meltz COO GENERAL COUNSEL SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-1.89%
|
$1,082
$2.25 P/Share
|
|
Dec 01
2023
|
Neha Krishnamohan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,459
-2.18%
|
$2,918
$2.25 P/Share
|
|
Dec 01
2023
|
Richard Thomas Williams CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-0.79%
|
$1,082
$2.25 P/Share
|
|
Sep 01
2023
|
Richard Thomas Williams CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-0.78%
|
$1,082
$2.35 P/Share
|
|
Sep 01
2023
|
Mark A Meltz COO GENERAL COUNSEL SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-1.85%
|
$1,082
$2.35 P/Share
|
|
Sep 01
2023
|
Neha Krishnamohan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,459
-2.13%
|
$2,918
$2.35 P/Share
|
|
Jun 01
2023
|
Neha Krishnamohan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,459
-2.09%
|
$5,836
$4.3 P/Share
|
|
Jun 01
2023
|
Mark A Meltz COO GENERAL COUNSEL SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-1.82%
|
$2,164
$4.3 P/Share
|
|
Jun 01
2023
|
Richard Thomas Williams CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-0.78%
|
$2,164
$4.3 P/Share
|
|
May 08
2023
|
James B. Tananbaum |
BUY
Open market or private purchase
|
Indirect |
1,780,000
+30.55%
|
$3,560,000
$2.8 P/Share
|
|
May 08
2023
|
Foresite Capital Management Iv, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,780,000
+30.55%
|
$3,560,000
$2.8 P/Share
|
|
May 05
2023
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
981,023
+26.39%
|
$1,962,046
$2.82 P/Share
|
|
May 05
2023
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
981,023
+26.39%
|
$1,962,046
$2.82 P/Share
|
|
May 04
2023
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
479,909
+7.85%
|
$959,818
$2.75 P/Share
|
|
May 04
2023
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
479,909
+7.85%
|
$959,818
$2.75 P/Share
|
|
May 02
2023
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
338,262
+6.18%
|
$676,524
$2.67 P/Share
|
|
May 02
2023
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
338,262
+6.18%
|
$676,524
$2.67 P/Share
|
|
May 01
2023
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
716,157
+12.99%
|
$1,432,314
$2.62 P/Share
|
|
May 01
2023
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
716,157
+12.99%
|
$1,432,314
$2.62 P/Share
|
|
Apr 28
2023
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
350,749
+7.97%
|
$701,498
$2.55 P/Share
|
|
Apr 28
2023
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
350,749
+7.97%
|
$701,498
$2.55 P/Share
|
|
Mar 01
2023
|
Neha Krishnamohan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,721
-2.49%
|
$8,605
$5.21 P/Share
|
|
Mar 01
2023
|
Mark A Meltz COO GENERAL COUNSEL SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
638
-2.28%
|
$3,190
$5.21 P/Share
|
|
Mar 01
2023
|
Richard Thomas Williams CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
638
-0.94%
|
$3,190
$5.21 P/Share
|
|
Feb 17
2023
|
Orbimed Advisors LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,100,000
+50.0%
|
-
|
|
Feb 17
2023
|
Carl L Gordon Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,100,000
+50.0%
|
-
|
|
Feb 17
2023
|
James B. Tananbaum |
BUY
Other acquisition or disposition
|
Indirect |
1,100,000
+35.77%
|
-
|
|
Feb 17
2023
|
Foresite Capital Management Iv, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
1,100,000
+35.77%
|
-
|
|
Dec 01
2022
|
Mark A Meltz COO GENERAL COUNSEL SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-1.9%
|
$3,787
$7.75 P/Share
|
|
Dec 01
2022
|
Neha Krishnamohan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,459
-2.07%
|
$10,213
$7.75 P/Share
|
|
Dec 01
2022
|
Richard Thomas Williams CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-0.79%
|
$3,787
$7.75 P/Share
|
|
Sep 01
2022
|
Richard Thomas Williams CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+26.75%
|
-
|
|
Sep 01
2022
|
Neha Krishnamohan CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
67,500
+49.45%
|
-
|
|
Sep 01
2022
|
Mark A Meltz COO GENERAL COUNSEL SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+46.76%
|
-
|
|
Mar 14
2022
|
Richard Thomas Williams CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Direct |
25,000
+37.13%
|
$200,000
$8.37 P/Share
|
|
Mar 11
2022
|
Richard Thomas Williams CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Direct |
15,000
+46.39%
|
$120,000
$8.64 P/Share
|
|
Feb 15
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
9,000
+0.26%
|
$81,000
$9.96 P/Share
|
|
Feb 15
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
9,000
+0.26%
|
$81,000
$9.96 P/Share
|
|
Feb 14
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
30,700
+0.44%
|
$276,300
$9.94 P/Share
|